[S] The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review

A tétel rövid nézete
dc.contributor.authorAbid, Naushad
dc.contributor.authorManaye, Sara
dc.contributor.authorNaushad, Hamzah
dc.contributor.authorCheran, Kaaviya
dc.contributor.authorMurthy, Chinmayee
dc.contributor.authorBornemann, Elisa A
dc.contributor.authorKamma, Hari Krishna
dc.contributor.authorAlabbas, Mohammad
dc.contributor.authorElashahab, Mohammed
dc.contributor.authorAlabbas, Mohammad (2024-) (xxx)
dc.contributor.submitterdepBelgyógyászati Intézet -- 84
dc.contributor.submitterdepÁOK
dc.contributor.submitterdepDebreceni Egyetem
dc.date.accessioned2024-06-04T13:15:46Z
dc.date.available2024-06-04T13:15:46Z
dc.date.oa2024-09-18
dc.date.updated2024-06-04T13:15:46Z
dc.description.abstractThere is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled trials (RCTs) have evaluated these two agents' clinical efficacy and safety in different manifestations of SLE. This study aims to review the randomized control trials involving these two agents systematically and to explain if any disparity is noticed in the primary and secondary outcomes between these two agents. This study is done according to Preferred Reporting Items for Systematic Reviews and Meta -Analyses (PRISMA) guidelines. After applying the inclusion criteria and quality assessment by independent reviewers and co-authors, relevant papers were identified, and data were extracted. The results have shown that RCTs involving Belimumab achieved primary endpoints; however, targeted endpoints were not achieved in studies involving Rituximab. It is concluded that despite the conflicting results obtained in clinical trials, both are effective in systemic lupus, as indicated in real -world clinical experience. However, better -designed multicenter studies evaluating these B -cell -targeting drugs are needed.
dc.description.correctorkzs
dc.identifier.citationCureus. -15 : 6 (2023), p. e40719, p. 1-10. -2168-8184
dc.identifier.doi10.7759/cureus.40719
dc.identifier.issn2168-8184
dc.identifier.opachttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM121746
dc.identifier.urihttps://hdl.handle.net/2437/370915
dc.identifier.urlhttps://www.cureus.com/articles/160267-the-safety-and-efficacy-of-rituximab-and-belimumab-in-systemic-lupus-erythematosus-a-systematic-review
dc.languageeng
dc.rights.accessopen access article
dc.rights.ownerszerző
dc.subject.otheridegen nyelvű folyóiratközlemény külföldi lapban
dc.subject.otherb-cell biology
dc.subject.otherlupus nephritis flare
dc.subject.othersystemic lupus
dc.subject.otherrituximab
dc.subject.otherbelimumab
dc.title[S] The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
FILE_UP_0_160267-the-safety-and-efficacy-of-rituximab-and-belimumab-in-systemic-lupus-erythematosus-a-systematic-review.pdf
Méret:
324.37 KB
Formátum:
Adobe Portable Document Format
Leírás:
kiadói változat
Letöltés
Gyűjtemények
Publikációs Adatbázis